SG Americas Securities LLC Raises Stock Holdings in Edwards Lifesciences Corporation $EW

SG Americas Securities LLC raised its stake in shares of Edwards Lifesciences Corporation (NYSE:EW) by 65.2% during the 1st quarter, according to its most recent filing with the SEC. The firm owned 980,609 shares of the medical research company’s stock after acquiring an additional 387,127 shares during the period. SG Americas Securities LLC’s holdings in Edwards Lifesciences were worth $78,527,000 as of its most recent SEC filing.

Other institutional investors have also recently made changes to their positions in the company. Norges Bank purchased a new position in shares of Edwards Lifesciences during the fourth quarter valued at approximately $803,686,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its holdings in Edwards Lifesciences by 278.3% in the third quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 5,584,646 shares of the medical research company’s stock worth $434,318,000 after purchasing an additional 4,108,270 shares during the last quarter. Viking Global Investors LP purchased a new stake in Edwards Lifesciences in the third quarter worth approximately $238,688,000. Marshall Wace LLP grew its position in Edwards Lifesciences by 66.1% in the 4th quarter. Marshall Wace LLP now owns 5,925,627 shares of the medical research company’s stock worth $505,160,000 after purchasing an additional 2,359,128 shares during the period. Finally, Price T Rowe Associates Inc. MD grew its position in Edwards Lifesciences by 147.6% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 2,126,755 shares of the medical research company’s stock worth $181,307,000 after purchasing an additional 1,267,918 shares during the period. Hedge funds and other institutional investors own 79.46% of the company’s stock.

Edwards Lifesciences Stock Performance

NYSE EW opened at $85.72 on Tuesday. The firm has a market cap of $49.36 billion, a price-to-earnings ratio of 45.59, a price-to-earnings-growth ratio of 2.19 and a beta of 0.87. The company has a quick ratio of 3.63, a current ratio of 4.42 and a debt-to-equity ratio of 0.06. The business has a 50-day moving average price of $83.52 and a 200-day moving average price of $83.13. Edwards Lifesciences Corporation has a twelve month low of $72.30 and a twelve month high of $89.60.

Edwards Lifesciences (NYSE:EW) last released its earnings results on Thursday, April 23rd. The medical research company reported $0.78 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.73 by $0.05. The firm had revenue of $1.65 billion during the quarter, compared to analysts’ expectations of $1.60 billion. Edwards Lifesciences had a return on equity of 15.19% and a net margin of 17.39%.The firm’s revenue was up 16.7% on a year-over-year basis. During the same quarter last year, the business posted $0.64 earnings per share. Edwards Lifesciences has set its FY 2026 guidance at 2.950-3.050 EPS and its Q2 2026 guidance at 0.700-0.760 EPS. As a group, equities research analysts predict that Edwards Lifesciences Corporation will post 3 EPS for the current fiscal year.

Analysts Set New Price Targets

EW has been the topic of several research analyst reports. Wolfe Research raised Edwards Lifesciences from a “peer perform” rating to an “outperform” rating and set a $92.00 price target on the stock in a report on Wednesday, April 1st. Evercore reaffirmed an “outperform” rating and issued a $93.00 price objective on shares of Edwards Lifesciences in a report on Friday, April 24th. Royal Bank Of Canada reiterated an “outperform” rating and set a $100.00 price objective on shares of Edwards Lifesciences in a research report on Tuesday, June 16th. Mizuho set a $95.00 target price on Edwards Lifesciences and gave the company an “outperform” rating in a report on Monday, April 13th. Finally, BTIG Research raised their target price on Edwards Lifesciences from $98.00 to $100.00 and gave the stock a “buy” rating in a research report on Friday, April 24th. Three analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and eight have issued a Hold rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $95.96.

Insiders Place Their Bets

In other news, CFO Scott B. Ullem sold 13,000 shares of Edwards Lifesciences stock in a transaction that occurred on Thursday, April 9th. The shares were sold at an average price of $80.04, for a total transaction of $1,040,520.00. Following the sale, the chief financial officer owned 39,699 shares in the company, valued at $3,177,507.96. This trade represents a 24.67% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP Donald E. Bobo, Jr. sold 23,145 shares of the business’s stock in a transaction on Wednesday, May 27th. The stock was sold at an average price of $86.42, for a total transaction of $2,000,190.90. Following the completion of the transaction, the vice president directly owned 98,611 shares in the company, valued at $8,521,962.62. This trade represents a 19.01% decrease in their position. The SEC filing for this sale provides additional information. Over the last quarter, insiders have sold 81,038 shares of company stock valued at $6,683,255. 0.31% of the stock is owned by company insiders.

Edwards Lifesciences Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.